The Endocrine Division uses technology, research, and novel gene therapies to enable physician-scientists in the Division of Endocrinology, Diabetes, and Bone Disease to identify new treatments.
At Mount Sinai St. Luke’s, The New York Obesity Research Center is the only federally funded obesity research center and the mission is to reduce the incidence of obesity and related diseases through leadership in basic obesity research, clinical research, epidemiology and public health, patient care, and public education.
Gaucher Disease is a genetic disorder that has an incidence of up to one in 850 live births in the Ashkenazi Jewish population. Mount Sinai and The Yale School of Medicine have generated a mouse model that recapitulates all features of Gaucher Disease, including severe osteoporosis. These studies should form the basis of new therapies for this crippling disease.
The Division of Endocrinology has expanded the Metabolism Institute, renaming it the Diabetes, Obesity, and Metabolism Institute (DOMI). Andrew Stewart, MD, Irene and Dr. Arthur M. Fishberg Professor of Medicine, is leading the institute along with six senior investigators with expertise in diabetes, islet cell biology, and islet autoimmunity.
And an artificial pancreas system is one of the most promising breakthroughs in Type 1 diabetes treatments in decades. As the first-ever comprehensive artificial pancreas clinical trial in New York State, Mount Sinai is collaborating with the University of Virginia School of Medicine (UVA) on this potentially historic project. This system has shown promising data in earlier studies leading to less hyperglycemia and reduced frequency of hypoglycemia compared to standard medical management.